瑞舒伐他汀对不同年龄高血压合并高脂血症患者内皮素和血清炎症因子水平的影响

Effect of rosuvastatin on the levels of endothelin and inflammatory factors in hypertension and hyperlipemia patients with different ages

目的：探讨瑞舒伐他汀对不同年龄高血压合并高脂血症患者内皮素和血清炎症因子水平影响的年龄差异性。方法：采用前瞻性队列研究，收集2013年1月–2014年3月门诊高血压合并高脂血症患者132例，其中青年组（男性年龄20~45岁，女性年龄20-55岁）42例，中年组（男性年龄45-65岁，女性年龄55-65岁）49例，老年组（65岁以上）41例。所有患者均给予常规抗高血压药物＋瑞舒伐他汀10 mg@d-1，观察时间为8周。对治疗前及治疗后8周各年龄组血清高敏C-反应蛋白（hs-CRP）、血浆内皮素（ET-1）、白介素-6（IL-6）水平进行统计分析。结果：瑞舒伐他汀治疗8周后，患者血脂水平、hs-CRP、IL-6有明显改善，ET-1水平无明显差异。扣除三组研究对象治疗前数据的影响，各年龄组经瑞舒伐他汀治疗后血脂水平，炎症因子（hs-CRP、IL-6水平）组间无明显差异。结论：瑞舒伐他汀对青年、中年、老年各年龄段高血压合并高脂血症患者的降脂疗效及降低炎症因子（hs-CRP、IL-6）的作用影响力相当，无年龄差异性。

Objective：To investigate the effects of rosuvastatin on endothelin and inflammatory factors in hypertension and hyperlipemia patients with different ages.Methods：Using prospective cohort study, 132 outpatients with hypertension and hyperlipemia, including 42 young patients, 49 middle-aged patients and 41 elderly patients, were assigned to receive 10 mg·d-1 of rosuvastatin and conventional antihypertensive drugs for 8 weeks. Serum hs-CRP, ET-1 and IL-6 level were measured at baseline and 8 weeks later for statistical analysis.Results：The levels of serum lipid, hs-CRP and IL-6 were improved signiifcantly, after the treatment of rosuvastatin for 8 weeks, while the level of ET-1 did not change signiifcantly. Deducting the inlfuence of baseline level, the levels of serum lipid, inlfammatory markers （hs-CRP and IL-6 level） of each age group treatment had no signiifcant differences after the treatment of rosuvastatin.Conclusion：The effect of lipid-lowering efifcacy and reducing inlfammatory factors （hs-CRP, IL-6） of rosuvastatin had no difference among young, middle-aged and elderly patients with hypertension combined with hyperlipemia.